Nurix Therapeutics, Inc. reported a net loss of $89.5 million for the fiscal quarter ended May 31, 2026, missing analyst estimates, as the company advanced its clinical pipeline and entered a major global partnership. The company posted a loss per share of $(0.81), which missed the analyst consensus estimate of $(0.74) by 9.46 percent, representing a 55.77 percent decrease from the loss of $(0.52) per share in the same period last year. Revenue for the quarter was $9.043 million, a 79.47 percent decrease from $44.056 million in the prior year, missing the analyst consensus estimate of $16.170 million by 44.08 percent. The decline in revenue was primarily due to the absence of $30 million in license revenue recorded from two Sanofi license extensions in the previous year.

Financial Performance

Research and development expenses increased to $87.7 million from $78.1 million, driven by clinical costs and contract manufacturing related to the acceleration of the bexobrutideg program. General and administrative expenses rose to $15.6 million from $14.3 million, largely due to increased legal costs for collaboration and business development activities. The company achieved a $2 million research milestone under its collaboration with Sanofi during the quarter.

Strategic Collaboration with Roche

Nurix announced a global license and collaboration agreement with Roche for bexobrutideg (NX-5948), a potential best-in-class BTK degrader, which includes potential total payments of up to $2.3 billion. This agreement comprises a $700 million upfront payment expected within 30 days of closing, subject to antitrust clearances. The deal covers the co-development and co-commercialization of bexobrutideg across malignant hematology, immunology, and neurology. Nurix will share 40% of development costs while Roche covers 60%, and profits and losses in the United States will be shared equally. Nurix is eligible for tiered royalties on ex-U.S. sales. The transaction is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Clinical and Pipeline Updates

The collaboration includes planned Phase 2 studies in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU). Nurix presented updated clinical data at the European Hematology Association (EHA) supporting bexobrutideg's profile. Updated Phase 1a results showed a median progression-free survival of 22.1 months and an objective response rate (ORR) of 83%. New Phase 1b results demonstrated an ORR of 92.9% in patients previously treated with a BTK inhibitor but naïve to BCL2 inhibitor therapy, and an ORR of 84.2% in BTKi-naïve patients. Enrollment continues in the pivotal Phase 2 DAYBreak CLL-201 trial, and preparations are underway for the Phase 3 DAYBreak CLL-306 trial, with the first patient dosing anticipated in mid-2026.

Financial Position

Cash, cash equivalents, and marketable securities were $443.5 million as of May 31, 2026, compared to $592.9 million as of November 30, 2025. The company expects to receive the $700 million upfront payment from Roche in the third fiscal quarter of 2026, which would bring pro-forma cash to approximately $1.14 billion. Nurix retains options to co-develop and co-commercialize other assets, including the STAT6 degrader NX-3911 with Sanofi and the IRAK-4 degrader GS-6791 with Gilead.

Condensed Statements of Operations Data

Baird analyst Joel Beatty has maintained an Outperform rating for Nurix Therapeutics, signaling continued confidence in the biotechnology company's prospects. The firm raised its price target for the stock to $33, an increase from the previous $26, indicating a revised valuation outlook and potential upside from current levels. This adjustment reflects an updated assessment of the company's financial trajectory and market position.

Rating and Price Target Details

The decision to raise the price target while retaining the Outperform rating underscores the analyst's belief in the stock's ability to deliver strong returns.

Nurix Therapeutics trades on the NASDAQ under the ticker symbol NRIX.